Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

527 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ranibizumab 0.5 mg for Diabetic Macular Edema with Bimonthly Monitoring after a Phase of Initial Treatment: 18-Month, Multicenter, Phase IIIB RELIGHT Study.
Pearce I, Banerjee S, Burton BJ, Chakravarthy U, Downey L, Gale RP, Gibson J, Pagliarini S, Patel J, Sivaprasad S, Andrews C, Brittain C, Warburton J; RELIGHT Study Group. Pearce I, et al. Among authors: downey l. Ophthalmology. 2015 Sep;122(9):1811-9. doi: 10.1016/j.ophtha.2015.05.038. Epub 2015 Jul 3. Ophthalmology. 2015. PMID: 26150052 Clinical Trial.
Previous Intravitreal Therapy Is Associated with Increased Risk of Posterior Capsule Rupture during Cataract Surgery.
Lee AY, Day AC, Egan C, Bailey C, Johnston RL, Tsaloumas MD, Denniston AK, Tufail A; United Kingdom Age-related Macular Degeneration and Diabetic Retinopathy Electronic Medical Records Users Group. Lee AY, et al. Ophthalmology. 2016 Jun;123(6):1252-6. doi: 10.1016/j.ophtha.2016.02.014. Epub 2016 Mar 18. Ophthalmology. 2016. PMID: 26996340
UK Neovascular Age-Related Macular Degeneration Database. Report 6: time to retreatment after a pause in therapy. Outcomes from 92 976 intravitreal ranibizumab injections.
Madhusudhana KC, Lee AY, Keane PA, Chakravarthy U, Johnston RL, Egan CA, Sim D, Zarranz-Ventura J, Tufail A, McKibbin M; UK AMD EMR Study Group. Madhusudhana KC, et al. Br J Ophthalmol. 2016 Dec;100(12):1617-1622. doi: 10.1136/bjophthalmol-2015-308077. Epub 2016 Mar 30. Br J Ophthalmol. 2016. PMID: 27030276
The UK Neovascular AMD Database Report 3: inter-centre variation in visual acuity outcomes and establishing real-world measures of care.
Liew G, Lee AY, Zarranz-Ventura J, Stratton I, Bunce C, Chakravarthy U, Lee CS, Keane PA, Sim DA, Akerele T, McKibbin M, Downey L, Natha S, Bailey C, Khan R, Antcliff R, Armstrong S, Varma A, Kumar V, Tsaloumas M, Mandal K, Egan C, Johnston RL, Tufail A. Liew G, et al. Among authors: downey l. Eye (Lond). 2016 Nov;30(11):1462-1468. doi: 10.1038/eye.2016.149. Epub 2016 Jul 15. Eye (Lond). 2016. PMID: 27419839 Free PMC article.
The United Kingdom Diabetic Retinopathy Electronic Medical Record Users Group, Report 1: baseline characteristics and visual acuity outcomes in eyes treated with intravitreal injections of ranibizumab for diabetic macular oedema.
Egan C, Zhu H, Lee A, Sim D, Mitry D, Bailey C, Johnston R, Chakravarthy U, Denniston A, Tufail A, Khan R, Mahmood S, Menon G, Akerele T, Downey L, McKibbin M, Varma A, Lobo A, Wilkinson E, Fitt A, Brand C, Tsaloumas M, Mandal K, Kumar V, Natha S, Crabb D; UK AMD and DR EMR Users Group. Egan C, et al. Among authors: downey l. Br J Ophthalmol. 2017 Jan;101(1):75-80. doi: 10.1136/bjophthalmol-2016-309313. Epub 2016 Dec 13. Br J Ophthalmol. 2017. PMID: 27965262
CLINICAL EVIDENCE OF THE MULTIFACTORIAL NATURE OF DIABETIC MACULAR EDEMA.
Chakravarthy U, Yang Y, Lotery A, Ghanchi F, Bailey C, Holz FG, Downey L, Weber M, Eter N, Dugel PU. Chakravarthy U, et al. Among authors: downey l. Retina. 2018 Feb;38(2):343-351. doi: 10.1097/IAE.0000000000001555. Retina. 2018. PMID: 28257378 Free PMC article. Clinical Trial.
527 results